Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors
Interventions
LCB02A
Drug
Lead sponsor
LigaChem Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Boston, Massachusetts • Lake Success, New York • Charleston, South Carolina + 1 more
Conditions
Advanced Cancer
Interventions
ZL-1201
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions
PF-07329640, sasanlimab, bevacizumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
Conditions
Non Small Cell Lung Cancer
Interventions
[89Zr]Zr-DFO-emapalumab
Drug
Lead sponsor
Nerissa T. Viola
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Conditions
Advanced Solid Tumors
Interventions
TGW101
Drug
Lead sponsor
Tagworks Pharmaceuticals BV
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania + 4 more
Conditions
Hepatocellular Carcinoma (HCC), Solid Tumors
Interventions
BAY3630942, BAY3547922
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor
Interventions
RYZ401
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 9 more
Conditions
Leukemia, Myeloid, Acute
Interventions
JNJ-63709178
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Detroit, Michigan • New York, New York • Charlotte, North Carolina + 4 more
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Drug · Biological · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy Volunteers
Interventions
GC021109, Placebo
Drug · Other
Lead sponsor
GliaCure, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Neptune City, New Jersey
Conditions
Advanced Tumors
Interventions
CPI-300
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Lake Mary, Florida • Cleveland, Ohio + 1 more
Conditions
Advanced Cancer
Interventions
BMS-986249, Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
19
States / cities
Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Conditions
Solid Tumor
Interventions
SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Newark, Delaware • Iowa City, Iowa • Westwood, Kansas + 6 more
Conditions
Toxicity;Chemical
Interventions
HOPO 14-1
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Plymouth, Michigan
Conditions
EGFR Mutation-Related Tumors
Interventions
NX-019
Drug
Lead sponsor
Nalo Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 4 more
Terminated Phase 1 Interventional Accepts healthy volunteers

First in Humans Study of JDTic

NCT01431586
Conditions
Cocaine Dependence
Interventions
JDtic
Drug
Lead sponsor
RTI International
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Advanced Solid Tumor
Interventions
YL201, YL201 and atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Interventions
TORL-1-23
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more
Conditions
Cervical Cancer
Interventions
Cemiplimab, ISA101b
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Orange, California
Recruiting Phase 1 Interventional Accepts healthy volunteers

IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study

NCT07596888
Conditions
HIV-1-infection
Interventions
IAP086 0.3 mcg/kg, IAP086 1 mcg/kg, IAP086 3 mcg/kg, IAP086 6 mcg/kg, IAP086 10 mcg/kg, IAP086 15 mcg/kg, IAP086 25 mcg/kg, IAP086 32 mcg/kg, IAP086 40 mcg/kg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina